Nasoxyl Paediatric (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasoxyl Paediatric, is an imidazoline nasal decongestant presented as a nasal spray for nasal use. It relieves nasal congestion associated with common cold, sinusitis and allergic rhinitis in children.

GNH USA supplies Nasoxyl Paediatric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is an imidazoline nasal decongestant used to alleviate upper‑respiratory tract congestion in children.

- Common cold: reduces nasal blockage and improves breathing. - Sinusitis: decreases mucosal swelling to facilitate sinus drainage. - Allergic rhinitis: alleviates congestion caused by allergen‑induced inflammation.

Nasal decongestant sprays may cause local and systemic reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Headache. - Altered taste perception. - Mild epistaxis.

Serious or Rare Side Effects: - Persistent nasal bleeding. - Severe allergic reaction (anaphylaxis). - Rebound congestion (rhinitis medicamentosa) after prolonged use.

Use Nasoxyl Paediatric with attention to specific safety considerations.

- Age restriction: not for children under 2 years unless advised by a healthcare professional. - Duration of use: limit to 3‑5 days to avoid rebound congestion. - Existing nasal conditions: avoid if nasal ulceration or severe trauma is present. - Concurrent MAO inhibitors: use with caution due to potential cardiovascular effects. - Pregnancy and lactation: consult a healthcare professional before use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other sympathomimetic agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase hypertensive risk. - Other nasal decongestants: additive vasoconstriction can raise blood pressure. - Sympathomimetic drugs: risk of excessive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt tachycardia response. - Antihypertensive agents: monitor blood pressure for changes. - Corticosteroid nasal sprays: assess for increased local irritation.